Tag Archives: Exiqon

Webinar on lncRNAs advancing therapeutics for cancer and heart disease

lncRNA

The authors of two new high impact papers in Nature and Science Translational Medicine describe how long non-coding RNAs are providing new therapeutic avenues in cancer and heart disease. Prof. Thomas Thum Director of the Institute of Molecular and Translational Therapeutic Strategies Hannover Medical School, Germany Prof. Thum will describe results from the recent Science Translational Medicine paper demonstrating that ...

Read More »

Upcoming webinar – lncRNAs advancing therapeutics for cancer and heart disease

lncRNA

Join Exiqon on Thursday 9 June and hear the authors of two new high impact papers in Nature and Science Translational Medicine describe how long non-coding RNAs are providing new therapeutic avenues in cancer and heart disease. Prof. Jean-Christophe Marine from K.U. Leuven in Belgium will present results from the recent Nature paper showing that melanoma cancer cells are addicted ...

Read More »

Webinar – lncRNA function and the use of Antisense LNA™ GapmeRs for knockdown of RNA

lncRNA

Watch our recent webinar and hear Dr. Zhen Xing from Liuqing Yang’s lab at MD Anderson Cancer Center present their work on long non-coding RNAs (lncRNA). In a recent Cell paper, they showed that knockdown of BCAR4 significantly reduced breast cancer metastasis in a mouse model. Hear about their approaches for the analysis of lncRNA function and get helpful tips. ...

Read More »

Long non-coding RNAs in the cardiovascular system

Dr. Stefanie Dimmeler – Dr. Reinier Boon – Katharina M. Michalik Katharina Michalik, Reinier Boon and Stefanie Dimmeler work at the Institute for Cardiovascular Regeneration at the Goethe University in Frankfurt, Germany. They are interested in microRNAs and long non-coding RNAs (lncRNAs) that control cardiovascular functions in endothelial cells. What is the background for your current project involving LNA™ GapmeRs? ...

Read More »

Exiqon Announces 2014 Grant Program for microRNA, long non-coding RNA or mRNA research

lncRNA

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the launch of its 2014 global research grant program, open to researchers from academic and non-profit institutions. “Exiqon aims to support our customers around the world in their everyday laboratory work and we are proud to offer excellent products for the analysis of any RNA in any biological system. With this grant ...

Read More »

Exiqon launches qPCR Array product for custom designed microRNA, mRNA and lncRNA assays

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of fully customizable qPCR arrays that allow for simultaneous detection of any microRNA, mRNA and lncRNA. As more scientists engage in next generation sequencing the need to verify gene expression discovered by sequencing grows. Researchers studying specific developmental or disease pathways are ...

Read More »

Exiqon launches advanced on-line tool for design of LNA gapmers for inhibition of mRNA and lncRNA

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced an extension to the LNA™ longRNA GapmeR product line with the launch of a novel on-line bioinformatics tool for the design of custom LNA™-gapmer antisense oligonucleotides for specific and efficient inhibition of mRNA and lncRNA. The new on-line LNA™ gapmer design tool allows scientists ...

Read More »

What are lncRNAs?

lncRNA

from Exiqon.com It was traditionally thought that the transcriptome would be mostly comprised of mRNAs, however advances in high-throughput RNA sequencing technologies have revealed the complexity of our genome. Non-coding RNA is now known to make up the majority of transcribed RNAs and in addition to those that carry out well-known housekeeping functions (e.g. tRNA, rRNA etc), many different types ...

Read More »

Exiqon launches LNA™ gapmers for inhibition of mRNA and lncRNA in functional studies

from Global Newswire Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of its LNA™ longRNA GapmeR products for specific and efficient inhibition of mRNA and lncRNA. The LNA™ longRNA GapmeRs are high affinity antisense oligonucleotides used for functional analysis, allowing researches to study the gene function and downstream biological consequences ...

Read More »